2013 | Aarkstore.in || Wet (Neovascular / Exudative) Macular Degeneration – Pipeline Review, H2 2012 by winaarkstore


									You can also request for sample page of above
mention reports on Customersupport@aarkstore.com
Price :
$ 2000 - PDF | $ 4000 - Site Licence | $ 6000 - Corporate Licence

Pages : 122

Global Markets Direct’s, Wet (Neovascular / Exudative) Macular Degeneration -
Pipeline Review, H2 2012, provides an overview of the indication’s therapeutic
pipeline. This report provides information on the therapeutic development for
Wet (Neovascular / Exudative) Macular Degeneration, complete with latest
updates, and special features on late-stage and discontinued projects. It also
reviews key players involved in the therapeutic development for Wet
(Neovascular / Exudative) Macular Degeneration. Wet (Neovascular /
Exudative) Macular Degeneration - Pipeline Review, Half Year is built using data
and information sourced from Global Markets Direct’s proprietary databases,
Company/University websites, SEC filings, investor presentations and featured
press releases from company/university sites and industry-specific third party
sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the
availability and relevance of data for the indicated disease.

- A snapshot of the global therapeutic scenario for Wet (Neovascular / Exudative)
Macular Degeneration.
 - A review of the Wet (Neovascular / Exudative) Macular Degeneration products
under development by companies and universities/research institutes based on
information derived from company and industry-specific sources.
 - Coverage of products based on various stages of development ranging from
discovery till registration stages.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under
development for Wet (Neovascular / Exudative) Macular Degeneration.
- Identify emerging players with potentially strong product portfolio and design
effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most
promising pipeline.
Table Of Contents

List of Tables 6
 List of Figures 7
 Introduction 8
 Global Markets Direct Report Coverage 8
 Wet (Neovascular / Exudative) Macular Degeneration Overview 9
 Therapeutics Development 10
 An Overview of Pipeline Products for Wet (Neovascular / Exudative) Macular
Degeneration 10
 Wet (Neovascular / Exudative) Macular Degeneration Therapeutics under
Development by Companies 12
 Wet (Neovascular / Exudative) Macular Degeneration Therapeutics under
Investigation by Universities/Institutes 15
 Late Stage Products 16
 Comparative Analysis 16
 Mid Clinical Stage Products 17
 Comparative Analysis 17
 Early Clinical Stage Products 18
 Comparative Analysis 18
 Discovery and Pre-Clinical Stage Products 19
 Comparative Analysis 19………………………
More Related Reports:


Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) – Pipeline
Review, H2 2012

Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline Review, H2

Diabetic Peripheral Neuropathy – Pipeline Review, H2 2012

Opioid-Induced Constipation (OIC) – Pipeline Review, H2 2012

Premature Labor (Tocolysis) – Pipeline Review, H2 2012
For More details about above & other Reports
plz contact :


Contact: Marketing team
Email: enquiry@aarkstore.com
URL: http://www.aarkstore.com

To top